KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Operating Leases (2019 - 2025)

Historic Operating Leases for Acadia Pharmaceuticals (ACAD) over the last 10 years, with Q3 2025 value amounting to $43.0 million.

  • Acadia Pharmaceuticals' Operating Leases rose 644.47% to $43.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.0 million, marking a year-over-year increase of 644.47%. This contributed to the annual value of $42.0 million for FY2024, which is 1205.65% down from last year.
  • Acadia Pharmaceuticals' Operating Leases amounted to $43.0 million in Q3 2025, which was up 644.47% from $44.6 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Operating Leases registered a high of $60.6 million during Q1 2021, and its lowest value of $40.4 million during Q3 2024.
  • For the 5-year period, Acadia Pharmaceuticals' Operating Leases averaged around $50.4 million, with its median value being $49.8 million (2023).
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Operating Leases skyrocketed by 94311.17% in 2021, and later tumbled by 1596.99% in 2024.
  • Acadia Pharmaceuticals' Operating Leases (Quarter) stood at $56.1 million in 2021, then decreased by 6.11% to $52.7 million in 2022, then decreased by 9.29% to $47.8 million in 2023, then decreased by 12.06% to $42.0 million in 2024, then rose by 2.35% to $43.0 million in 2025.
  • Its last three reported values are $43.0 million in Q3 2025, $44.6 million for Q2 2025, and $44.6 million during Q1 2025.